As more specific and potent AR-targeting therapeutics are being used in the clinic, more AR+ adenocarcinomas are being turned (reprogrammed) to AR−/lo NE-like tumors called CRPC-NE24,34 or AR pathway-independent AR−NE− tumors called double-negative PCa (or DNPC35). This evidence concerns the gene AR and posterior cortical atrophy.